FL-BOW-GROUP
29.7.2021 15:17:11 CEST | Business Wire | Press release
BOW Group today announced that it has successfully completed the acquisition of Musart.com , a fast-growing online destination to buy original artworks and licensed products. This transaction will allow BOW Group to seize new opportunities in the booming digital art market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005637/en/
“BOW Group and Musart share the same passion for good yet accessible design that brings emotions to consumers at every moment of the day,” said Boris Brault, BOW Group Founder and CEO. “Together, with Musart’s unique product curation and established relationships with leading institutions, we can conquer the thriving online art market thanks to our global ecommerce, logistics and development capabilities. With Musart in our portfolio, we are expanding our offering and enhancing the growth potential of our business beyond IoT and lifestyle objects. Today, the art world is fundamentally changing, disrupted with new players and media; we want to participate in that shift by helping consumers get access to art pieces and accessories, under different forms, at every price points.”
Since its inception in 2014, Musart has sold thousands of pieces of collectibles. Founded by French Art-Lover and Entrepreneur Vincent Gregoire, Musart’s mission is to make art accessible, giving anyone the opportunity to «own a piece of museum».
Partnerships with world-class museums, foundations and cultural organizations allow Musart to bring not only exclusive and authentic items, but also, to honor iconic artists such as Basquiat, Cattelan, Da Vinci, Dali, Haring, Hokusai, Kahlo, Klimt, Kusama, Magritte, Michelangelo, Miró, Modigliani, Mondrian, Picasso, Pollock, Van Gogh, Warhol. Licensed items, numbered and signed pieces include the world famous Kaws, Medicom Toy Be@rbricks and Kidrobot, as well as new promising talents. The selection spans multiple product categories: sculptures, home decor and office accessories, stationary, books, clothing, etc... with prices ranging from $20 to $20,000.
Customers receive not only an art piece but also a short biography of the corresponding artist for each purchase, proving Musart’s commitment to democratizing art and its educative vocation. Headquartered in Miami, Musart has first experienced a retail journey and embarked into a successful digital experience with its own website and 5-stars Central Seller page on Amazon, gathering today more than 1000 references and a highly active community of collectors.
By joining BOW Group, Musart will benefit from the group’s 360° platform, including a mature D2C digital ecosystem, multiple warehouse locations to serve consumers around the globe and its R&D center BOW Industries to handle its licensed and private label activities. One of the first objectives is to expand Musart’s sales activity outside the US, especially in Europe. While Musart will undoubtedly diversify BOW Group’s offering from a B2C standpoint, it will also meet the demand of B2B and Corporate customers with a whole new range of exciting gift objects.
Musart Founder Vincent Gregoire said: “I’m thrilled to join BOW Group with whom we share the same entrepreneurial mindset and consumer-driven approach. This integration marks a new chapter for Musart, one that will definitely help us reach our full potential at a global scale and embrace the new disruptive changes of our industry, such as NFTs. Leveraging BOW’s existing digital resources, ecommerce and supply chain infrastructure will take our business to another level, bringing innovative online experiences such as AR technology while continuing to make art accessible to anyone.”
Follow Musart
Instagram: https://www.instagram.com/musartboutique/
Facebook: https://www.facebook.com/musartboutique/
About BOW Group
BOW Group is a global player and multi-skilled platform operating worldwide with two consumer brands: Lexon , the design object editor, and MyKronoz , the IoT specialist - both powered by its own R&D and manufacturing center, BOW Industries. In addition, BOW Group owns the luxury concept-store chain Legacy .
Every year, BOW Group sells about 2 million pieces of products in 90 countries and across 9000 points of sales, thanks to its international recognition and network of leading designers celebrated with more than 200 Awards received, including 7 Red Dot Design Awards won by its two brands in 2021.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
Since July 2015, BOW has opened up its capital to NextStage AM , then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
